[Frontotemporal dementia: therapeutic possibilities].
In order to treat frontotemporal dementia (FTD) we must first evaluate the patient's medical condition, as well as his or her social setting (caregiver, financial resources, home characteristics). Primary health-care team must receive information about the patient's disease, and the family should be informed about the disease itself and the social resources they can ask for. It is advisable to formulate a therapeutic scheme including some counsels to improve the suitability of environment, social help measures, behaviour therapy, cognitive stimulation and pharmacological treatment. Atypical antipsychotics have improved "positive symptoms" as logorrhoea, wandering, agitation and aggression, without impairing cognitive function. Selective serotonin reuptake inhibitors improve depressive symptoms, compulsions, food craving and disinhibition. A few reports suggest that idazoxan (alpha 2-noradrenergic antagonist) can improve attention, verbal fluency and planning efficiency. In some cases with "FTD and parkinsonism linked to chromosome 17" it could be justified to perform a genetic analysis to the offspring, in order to know if genetic counseling is necessary. An inflammatory reaction has been observed in brain damaged areas, and therefore antiinflammatory treatment efficacy should be investigated. It would also be interesting to look for neuroprotective agents that lessen the tau protein abnormality. All types of receptors which are involved in FTD should be identified, and then their selective agonists or antagonists could be administered in synergic combinations. We hope that all genetic alterations producing or facilitating FTD are eventually known, and harmless curative means are developed.
Robles Bayón
A
A
Servicio de Neurología, Hospital Clínico Universitario, Santiago de Compostela, La Coruña.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D003704:Dementia / Q000188:drug therapy* / Q000473:pathology*; D005625:Frontal Lobe / Q000473:pathology*; D006801:Humans; D019329:Idazoxan / Q000627:therapeutic use*; D011320:Primary Health Care; D013702:Temporal Lobe / Q000473:pathology*
D000317:Adrenergic alpha-Antagonists; D019329:Idazoxan